Pricing
  1. US-listed companies
  2. Regenicin, Inc.
  3. Raw

Regenicin, Inc.【RGIN】

Market cap
$15.35K
P/E ratio
SummaryFinancials
Back to summarized table
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2014		Sep 30,
2015		Sep 30,
2016		Sep 30,
2017		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022
     Cash----------1,859-
     Common stock of Amarantus----------2,750925
               Total current and total assets3396,33531359,83387,79356,4335,3154,1414,609-
     Accounts payable739,327211360,228262,934280,96167,532138,29888,65993,674-
     Accrued expenses - other (related party of $65,471 and $46,713)---------174,438441,394-
     Accrued salaries - officers-----122334-
     Promissory note payable-42,16052,220------175,000175,000-
     Convertible promissory note - officer--264,417295,617-----335,683335,683-
     Loan payable-10,00010,00010,00010,00010,00010,00010,00010,00010,00010,00010,000
     Loans payable - officer----------82,235-
               Total current and total liabilities14442233445-
     Series A 8% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding----------885-
     Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding88,23793,837120,159139,601157,914157,914157,914157,914157,914157,914157,914-
     Additional paid-in capital679910101010101010-
     Accumulated deficit-4,660,332-8,187,901-13,092,713-10,952,591-10,709,992-11,799,894-12,773,831-13,332,889-14,090,395-14,649,98616-
      Less: treasury stock; 4,428,360 shares at par4,428---------4,428-
               Total stockholders' deficiency------1,468,008-2,441,445-3,000,053-3,727,685-4,287,276-5,164,378-
               Total liabilities and stockholders' deficiency3396,33531-----4,609-